– UK, Worthing – Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specializing in allergy vaccines, today announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately.
“I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy over many years, and I have no doubt Anthony and Simon will be invaluable members of the Board, bringing extensive business and innovation sector experience.” said Non-Executive Chairman, Peter Jensen.
Anthony Parker represents Southern Fox Investments Limited and Simon Shen represents ZQ Capital Management Limited acting through its affiliate SkyGem Acquisition Limited.
About Anthony Parker
Anthony Parker has worked in investment banking and fund management for over thirty years and, as Founder and Partner of Beagle Partners LLP, which advises Southern Fox, has managed or advised on multiple UK innovation technology investments. He is the Founder and Chairman of Argonaute RNA Ltd, a UK-based research company developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Prior to this, Anthony held senior roles at ING Barings and was an equity analyst for Cazenove & Co. He holds an Investment Management Certificate from the Institute of Investment Management and Research.
About Simon Shen
Simon Shen founded the investment and advisory firm, ZQ Capital, in 2015. Prior to that, he spent more than a decade as an investment banker advising international companies on their capital markets activities. He was Managing Director and Head of the China Financial Institutions Group at Barclays from 2011 to 2015, following earlier roles at Goldman Sachs, Lehman Brothers and McKinsey & Company. He has a BA in mathematics and economics from Wesleyan University.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focused on treating and diagnosing allergic disorders, including aluminum-free immunotherapy vaccines that can potentially cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost the performance of vaccines outside allergies are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group employs c.600 employees.
For more information: https://www.allergytherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
